Promising Phase III Results for Once-a-Month HIV Treatment

Breakthrough in HIV Treatment: Once-a-Month Injectable Shows Promise

Janssen and ViiV Healthcare have unveiled encouraging results from two phase III trials of a novel, once-monthly injectable HIV treatment. This regimen combines ViiV's experimental integrase inhibitor, cabotegravir, with Janssen's Edurant (rilpivirine), offering a significant reduction in treatment frequency from daily oral medication to just 12 injections annually.

Clinical Trial Outcomes

The ATLAS study, one of the two pivotal trials, demonstrated that the cabotegravir and Edurant combination was non-inferior to the standard daily oral three-drug regimen. Specifically, 1.6% of participants on the two-drug regimen had plasma HIV-1 RNA levels of at least 50 copies per millilitre (c/mL) at week 48, compared to 1% in the standard therapy group. Virologic suppression rates were closely matched at 92.5% for the injectable regimen and 95.5% for the oral therapy.

Similarly, the FLAIR study showed that the once-monthly treatment was non-inferior to ViiV's Triumeq, with 2% of patients on cabotegravir/Edurant having plasma HIV-1 RNA levels of at least 50 c/mL, compared to 2.5% for Triumeq patients. Both studies reported low rates of confirmed virologic failure, underscoring the regimen's efficacy and safety.

Patient Preference and Future Directions

A notable aspect of the trials was the overwhelming patient preference for the long-acting injectable regimen over their previous oral therapy. This preference underscores the potential of this treatment to improve adherence and quality of life for people living with HIV.

ViiV Healthcare is preparing to submit regulatory applications for the once-monthly injectable regimen later this year. Additionally, the company is exploring a formulation that could extend the dosing interval to every two months, further reducing the treatment burden.

Competitive Landscape

While ViiV's innovation represents a significant advancement, it faces competition from Gilead, which currently dominates the HIV treatment market. Gilead's focus on triple therapy and its development of a long-acting capsid inhibitor, GS-6207, highlight the ongoing evolution of HIV treatment strategies. However, the promising results from ViiV's phase III trials position the once-monthly injectable regimen as a potential game-changer in the fight against HIV.

This development not only offers a more convenient treatment option but also marks a pivotal shift towards reducing the daily pill burden, a longstanding challenge in HIV therapy. As the medical community awaits further regulatory developments, the once-monthly injectable regimen stands as a beacon of hope for millions living with HIV worldwide.